Author of 1 Presentation
SS 11.8 - The value of MRI-defined sarcopenia in predicting hepatic decompensation and mortality in patients with chronic liver disease
Abstract
Purpose
To explore whether sarcopenia, diagnosed by an abbreviated MRI protocol is a risk factor for hepatic decompensation and mortality in patients with chronic liver disease (CLD).
Material and methods
In this retrospective single-centre study, we included 265 patients (164 men, mean age 54 ±16 years) with CLD who had undergone MRI of the liver between 2010 and 2015. Transverse psoas muscle thickness (TPMT) was measured on unenhanced and contrast-enhanced T1-weighted and T2-weighted axial images. Sarcopenia was defined by height-adjusted and gender-specific cut-offs in women as TPMT <8mm/m and in men as TPMT <12mm/m, respectively. Patients were further stratified into three prognostic stages according to the absence of advanced fibrosis (FIB-4<1.45, non-advanced CLD), compensated-advanced CLD (cACLD); and decompensated-advanced CLD (dACLD).
Results
The inter-observer agreement for the TPMT measurements (κ=0.98; 95% confidence-interval [CI]: 0.96-0.98), as well as the intra-observer agreement between the three image sequences (κ=0.99; 95%CI: 0.99-1.00) were excellent. Sarcopenia was not predictive of further hepatic decompensation. In patients with cACLD and dACLD, sarcopenia was a risk factor for mortality (cACLD: hazard ratio (HR): 3.13, 95%CI: 1.33-7.06; dACLD: HR: 2.34, 95%CI: 1.29-4.26) on univariate analysis. After adjusting for sex, Child-Turcotte-Pugh score, serum creatinine, and sodium levels, sarcopenia (adjusted HR: 2.66, 95% CI: 1.05-6.75) remained an independent risk factor for mortality in patients with cACLD.
Conclusion
Sarcopenia can be easily evaluated by a short MRI exam without the need for contrast injection. Sarcopenia is a risk factor for mortality, especially in patients with cACLD.
Video-on-demand
Author of 1 Presentation
SS 11.8 - The value of MRI-defined sarcopenia in predicting hepatic decompensation and mortality in patients with chronic liver disease (ID 439)
Abstract
Purpose
To explore whether sarcopenia, diagnosed by an abbreviated MRI protocol is a risk factor for hepatic decompensation and mortality in patients with chronic liver disease (CLD).
Material and methods
In this retrospective single-centre study, we included 265 patients (164 men, mean age 54 ±16 years) with CLD who had undergone MRI of the liver between 2010 and 2015. Transverse psoas muscle thickness (TPMT) was measured on unenhanced and contrast-enhanced T1-weighted and T2-weighted axial images. Sarcopenia was defined by height-adjusted and gender-specific cut-offs in women as TPMT <8mm/m and in men as TPMT <12mm/m, respectively. Patients were further stratified into three prognostic stages according to the absence of advanced fibrosis (FIB-4<1.45, non-advanced CLD), compensated-advanced CLD (cACLD); and decompensated-advanced CLD (dACLD).
Results
The inter-observer agreement for the TPMT measurements (κ=0.98; 95% confidence-interval [CI]: 0.96-0.98), as well as the intra-observer agreement between the three image sequences (κ=0.99; 95%CI: 0.99-1.00) were excellent. Sarcopenia was not predictive of further hepatic decompensation. In patients with cACLD and dACLD, sarcopenia was a risk factor for mortality (cACLD: hazard ratio (HR): 3.13, 95%CI: 1.33-7.06; dACLD: HR: 2.34, 95%CI: 1.29-4.26) on univariate analysis. After adjusting for sex, Child-Turcotte-Pugh score, serum creatinine, and sodium levels, sarcopenia (adjusted HR: 2.66, 95% CI: 1.05-6.75) remained an independent risk factor for mortality in patients with cACLD.
Conclusion
Sarcopenia can be easily evaluated by a short MRI exam without the need for contrast injection. Sarcopenia is a risk factor for mortality, especially in patients with cACLD.